Table 2 Patient characteristics at baseline (FAS)
Placebo | Tofogliflozin | ||||
|---|---|---|---|---|---|
10 mg | 20 mg | 40 mg | |||
n | 56 | 57 | 58 | 58 | |
Age (years), Mean (SD) | 56.8 (9.9) | 58.6 (9.8) | 56.6 (10.2) | 57.0 (9.1) | |
Gender, n (%) | Male | 37 (66.1%) | 38 (66.7%) | 39 (67.2%) | 39 (67.2%) |
Female | 19 (33.9%) | 19 (33.3%) | 19 (32.8%) | 19 (32.8%) | |
Body weight (kg), Mean (SD) | 71.20 (12.64) | 67.26 (12.67) | 68.06 (15.82) | 68.72 (11.91) | |
BMI (kg/m2), Mean (SD) | 26.00 (4.11) | 25.07 (3.53) | 24.99 (4.55) | 25.78 (4.10) | |
HbA1c (%), Mean (SD) | 8.41 (0.78) | 8.45 (0.75) | 8.34 (0.81) | 8.37 (0.77) | |
Fasting plasma glucose (mg/dL), Mean (SD) | 168.8 (24.9) | 170.2 (32.4) | 168.7 (29.6) | 167.9 (37.0) | |
eGFR (mL/min/1.73 m2), Mean (SD) | 83.78 (17.68) | 84.90 (20.15) | 86.78 (19.62) | 86.00 (18.18) | |
Systolic blood pressure (mmHg), Mean (SD) | 128.3 (13.7) | 128.0 (15.6) | 131.3 (12.9) | 129.3 (12.5) | |
Diastolic blood pressure (mmHg), Mean (SD) | 76.7 (11.4) | 78.6 (10.6) | 79.2 (11.7) | 78.7 (9.0) | |
Duration of diabetes (years), Mean (SD) | 6.0 (6.1) | 6.3 (7.1) | 6.4 (5.1) | 6.7 (5.5) | |
Prior treatment of diabetes | Yes | 16 (28.6%) | 15 (26.3%) | 23 (39.7%) | 16 (27.6%) |
No | 40 (71.4%) | 42 (73.7%) | 35 (60.3%) | 42 (72.4%) | |